Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds

Randy M. Wadkins, Janice L. Hyatt, Carol C. Edwards, Lyudmila Tsurkan, Matthew R. Redinbo, Craig E. Wheelock, Paul D. Jones, Bruce D. Hammock and Philip M. Potter
Molecular Pharmacology March 2007, 71 (3) 713-723; DOI: https://doi.org/10.1124/mol.105.021683
Randy M. Wadkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice L. Hyatt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol C. Edwards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyudmila Tsurkan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew R. Redinbo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig E. Wheelock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul D. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce D. Hammock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip M. Potter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Carboxylesterases (CE) are ubiquitous enzymes that hydrolyze numerous ester-containing xenobiotics, including complex molecules, such as the anticancer drugs irinotecan (CPT-11) and capecitabine and the pyrethroid insecticides. Because of the role of CEs in the metabolism of many exogenous and endogenous ester-containing compounds, a number of studies have examined the inhibition of this class of enzymes. Trifluoromethylketone-containing (TFK) compounds have been identified as potent CE inhibitors. In this article, we present inhibition constants for 21 compounds, including a series of sulfanyl, sulfinyl, and sulfonyl TFKs with three mammalian CEs, as well as human acetyl- and butyrylcholinesterase. To examine the nature of the slow tight-binding inhibitor/enzyme interaction, assays were performed using either a 5-min or a 24-h preincubation period. Results showed that the length of the preincubation interval significantly affects the inhibition constants on a structurally dependent basis. The TFK-containing compounds were generally potent inhibitors of mammalian CEs, with Ki values as low as 0.3 nM observed. In most cases, thioether-containing compounds were more potent inhibitors then their sulfinyl or sulfonyl analogs. QSAR analyses demonstrated excellent observed versus predicted values correlations (r2 ranging from 0.908–0.948), with cross-correlation coefficients (q2) of ∼0.9. In addition, pseudoreceptor models for the TKF analogs were very similar to structures and models previously obtained using benzil- or sulfonamide-based CE inhibitors. These studies indicate that more potent, selective CE inhibitors, containing long alkyl or aromatic groups attached to the thioether chemotype in TFKs, can be developed for use in in vivo enzyme inhibition.

Footnotes

  • This work was supported in part by National Institutes of Health (NIH) grants CA76202, CA79763, CA98468, CA108775, Cancer Center Core grant P30-CA21765, National Institute of Environmental Health Sciences (NIEHS) grant R37-ES02710, NIEHS Superfund grant P42-ES04699, NIEHS Center for Environmental Health Sciences grant P30-ES05707, and by the American Lebanese Syrian Associated Charities. C.E.W. was supported by a Japanese Society for the Promotion of Science (JSPS) postdoctoral fellowship and NIH postdoctoral training grant T32-DK07355-22. P.D.J. was supported by NIH/National Heart, Lung, and Blood Institute Ruth L. Kirschstein National Research Service Award grant F32-HL078096.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.105.021683.

  • ABBREVIATIONS: CE, carboxylesterase; CPT-11, irinotecan; TFK, trifluoromethyl ketone; AChE, acetylcholinesterase; QSAR, quantitative structure-activity relationship; 3D, three-dimensional; BChE, butylcholinesterase; h, human; r, rabbit; Mp, melting point; o-NPA, o-nitrophenyl acetate.

  • ↵1 Current affiliation: Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.

    • Received December 13, 2005.
    • Accepted December 12, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 71 (3)
Molecular Pharmacology
Vol. 71, Issue 3
1 Mar 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds

Randy M. Wadkins, Janice L. Hyatt, Carol C. Edwards, Lyudmila Tsurkan, Matthew R. Redinbo, Craig E. Wheelock, Paul D. Jones, Bruce D. Hammock and Philip M. Potter
Molecular Pharmacology March 1, 2007, 71 (3) 713-723; DOI: https://doi.org/10.1124/mol.105.021683

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds

Randy M. Wadkins, Janice L. Hyatt, Carol C. Edwards, Lyudmila Tsurkan, Matthew R. Redinbo, Craig E. Wheelock, Paul D. Jones, Bruce D. Hammock and Philip M. Potter
Molecular Pharmacology March 1, 2007, 71 (3) 713-723; DOI: https://doi.org/10.1124/mol.105.021683
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics